Financial reports
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
17 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Results of Operations and Financial Condition
5 Jan 24
8-K
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Oct 23
8-K/A
Submission of Matters to a Vote of Security Holders
14 Sep 23
8-K
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
8-K
Departure of Directors or Certain Officers
2 Jun 23
8-K
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4 May 23
Registration and prospectus
S-3
Shelf registration
8 Mar 24
S-8
Registration of securities for employees
18 Mar 22
424B5
Prospectus supplement for primary offering
17 Dec 21
424B5
Prospectus supplement for primary offering
28 May 21
424B3
Prospectus supplement
15 Apr 21
S-3
Shelf registration
2 Apr 21
S-8
Registration of securities for employees
22 Mar 21
D
$6.47M in options / securities to be acquired, sold $6.47M, 4 investors
22 Dec 20
424B5
Prospectus supplement for primary offering
10 Dec 20
FWP
Free writing prospectus
10 Dec 20
Proxies
DEFA14A
Additional proxy soliciting materials
16 May 23
DEF 14A
Definitive proxy
16 May 23
PRE 14A
Preliminary proxy
5 May 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 21
DEF 14A
Definitive proxy
13 Apr 21
PRE 14A
Preliminary proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
Other
EFFECT
Notice of effectiveness
16 Apr 21
CORRESP
Correspondence with SEC
13 Apr 21
UPLOAD
Letter from SEC
7 Apr 21
EFFECT
Notice of effectiveness
8 May 19
CORRESP
Correspondence with SEC
3 May 19
EFFECT
Notice of effectiveness
5 Jan 18
CORRESP
Correspondence with SEC
3 Jan 18
UPLOAD
Letter from SEC
29 Dec 17
CT ORDER
Confidential treatment order
6 Nov 17
EFFECT
Notice of effectiveness
2 Nov 17